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ABSTRACT 
Respiratory diseases are the leading source of morbidity and death for millions around the world of all ages. A 2019 coronavirus outbreak has 
occurred in China and is spread quickly throughout nearly all across the world. To introduce prevention measures that have contributed to a 
sudden upturn in the rate of cases around the globe, several nations responded too late. It has prompted nations to close the borders, halted 
companies, kept people inside their homes, and numerous other measures to prevent their spread. 
We systematically searched on Google scholar, PubMed, LitCovid, and MedRxiv using the search terms coronavirus, severe acute respiratory 
syndrome, 2019-nCoV, SARS-CoV-2, SARS-CoV, MERS-CoV, COVID-19, and vaccine for published articles. Present or performed clinical studies were 
found on the ClinicalTrials. gov, the Chinese Clinical Trial Registry, and the International Clinical Trial Registry site using the disease searches 
phrase coronavirus infection. 
Many repurposed drugs, including antivirals, antibiotics, monoclonal antibodies, corticosteroids, and others, were found to be effective against the 
novel COVID-19. Governments, private firms, researchers, and non-profit organizations are working hard to create a COVID-19 vaccine. 
In addition to the new medicines and old drug clinical testing, SARS-CoV-2 vaccines must also be designed and developed. Moreover, positive news 
in the development of vaccines suggests that new vaccines will be available on the market soon and a bowl of immunity against this virus can be 
established, thus limiting the spread and eradication of this deadly virus from the surface of the world as with so many viruses. 
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INTRODUCTION 
The lives of over one billion populations globally are affected by 
respiratory illnesses and the main reason for death and morbidity 
[1]. A wide variety of severe disorders are defined by chronic 
respiratory diseases (CRD), i.e. chronic airway diseases and other 
structures of the lungs [2]. Unfortunately, the public awareness of 
CRDs and research funding are proportionately lower than that of 
other diseases such as cardiovascular, tumors, heart attack, diabetes, 
and Alzheimer's [3]. In both developed and developing countries, 
CRDs pose a public health threat because of their incidence and 
economic implications [4]. 
The novel coronavirus 2019 (2019-nCoV) or severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), as it is now 
known, is expanding quickly from its origin (Wuhan, China) since 
December to the rest of the world [5]. A swift response team to 
assist the province of Hubei and the Wuhan City health agencies and 
perform epidemiological investigations was sent out on December 
31st, 2019, by the Chinese Center for Disease Control and 
Prevention (China CDC) [6]. The World Health Organisation (WHO) 
has reacted promptly by preparation of the production of diagnostic 
systems; issuing patient surveillance, test selection, and care 
guidelines; and updating epidemic information [7]. On 12 January 
2020, the isolated pathogen was named 2019-CoV after quick 
isolation from a patient. And the International Taxonomy Committee 
for Viruses reported on 11 February that its official classification is 
SARS-CoV-2. On the same day, the WHO declared Corona Virus 
Disease-19 (COVID-19), the official name of the virus causing the 
disease [8, 9]. The WHO declared a pandemic on March 11, 2020 [10]. 
COVID-19 is a modern disorder that has distinct biological features, 
clinical signs, and manifestations of the imaging, while important 
clinical management advancements have been achieved [11]. Tyrell 
and Bynoe, who grown the pathogen from patients with common 
colds, i.e., first identified coronavirus in 1966 [12]. Bats are thought to 
be a natural storehouse for SARS-CoV-2, but human infection has been 
proposed by an intermediate host like pangolins [13]. 
The COVID-19 epidemic features high contagious levels and 
comparatively high death rates, especially among elderly people 
over 80 y of age [14]. China, the first COVID-19 affected country, 
shows an 8 percent fatality rate in 70–79 y, and almost double for 
people aged 80 or over. An analogous pattern is observed in Italy, 
42.2% of those who died of COVID-19 were in the 80 to 89-year age 
group, and 32.4% were in the 70 to 79-years group, whereas the 
worldwide average fate rate is 3.4 percent. The aging population is, 
therefore a serious worry in estimating death and morbidity during 
the coronavirus pandemic in the world [15]. 
Experiences with outbreaks like Middle East Respiratory Syndrome 
(MERS), pandemic influenza, and others demonstrated the 
immediate need to extend public health efforts to shed light on and 
classify the epidemiology of the emerging viruses [16]. The epidemic 
has been somewhat slowed, due to drastic safety precautions taken 
in China. However, it quickly spread throughout the globe, causing 
extreme worry [17]. Many nations have responded too late for 
mitigation steps that have led to a sudden rise in cases globally [18].  
A reverse transcription chain reaction (RT-PCR) assay has been 
produced and is currently in use for COVID-19. Whilst RT-PCR 
remains the reference standard for making a conclusive diagnosis of 
COVID-19, the high false negatives, as well as the inaccessibility of 
the RT-PCR assay, limited easy diagnosis for infected patients in the 
early stages of the epidemic. In combating this infectious disease, 
radiological exams, especially thin-slice chest CT, plays an important 
role [19]. Personal and environmental hygiene maintenance are the 
key measures to protect from the current virus infection [20]. 
Timeline of SARS-CoV-2 first case registered to the pandemic 
declaration by WHO shows in fig. 1. 
Different strains OF CoV 
COVID-19 is the 7th coronavirus that has been identified to infect 
humans [21]. Six various CoV strains are known to infect humans 
before SARS-CoV-2. HCoV229E (229E), HCoV-OC43 (OC43), HCoV-
NL63 (NL63), HCoV-HKU1 (HKU1), SARS-CoV, and MERS-CoV are also 
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included in these groups. The different types of CoV strains that affect 
humans are listed in table 1 [22-24]. SARS-CoV is a pathogenetic agent 
that caused over 8,000 human infections and 774 deaths in China 
during a 2002–2003 serious respiratory illness outbreak and since 
2012, the MERS-CoV causes 2458 infections and 848 deaths by 
2019 as the disease-causing pathogen for the outbreak of serious 
breathing diseases in the Middle East [21, 22, 25]. The SARS and MERS 
coronavirus are indicative of a major danger to public health [26]. 
 
 
Fig. 1: Shows the timeline of coronavirus from the first case registered to the declaration of a pandemic by WHO 
 
Table 1: Different strains of CoV affecting humans 
S. No. Type of strain 
1 Alpha coronavirus-229E 
2 Beta coronavirus-OC43 
3 Alpha coronavirus-NL63 





Table 2: List of top 5 countries having maximum cases registered along with their classification of transmission as of 11th December 2020 
Country Cases– 
cumulative total 
DEATH-cumulative total Case fatality rate 
(%) 
Transmission classification 
United States 15,203,208 287,384 1.89% Community transmission 
India 9,796,769 142,186 1.45% Clusters of cases 
Brazil 6,728,452 178,995 2.66% Community transmission 
Russia 2,569,126 45,280 1.76% Clusters of cases 
France 2,283,752 56,280 2.46% Community transmission 
 
Up to December 11, 2020, the top 5 countries with the most COVID-
19 cases and other information are listed in table 2. CoV is common 
in all species of bats but can also be found in many other species, 
such as cats, dogs, horses, humans, mice, pigs, and whales. They can 
cause the variable intensity of respiratory, gastrointestinal, liver, or 
neurological conditions [24]. The positive-sense, uniform RNA virus 
of the genus beta coronavirus was found to be SARS-CoV-2 [27]. 
CoV’s ability to propagate rapidly is the deadliest feature [28]. In 
early transmission studies, the linkage between the fish market and 
the sea creatures market in China with many early infections was 
reported. Later, new infections were spread by the virus mainly 
through transmission between humans [29]. Globally, the CoV 
incubation period is 3-7 d. About 80% of infectious case scenarios 
persist mild or asymptomatic, 15% are severe or 5% are critical, and 
ventilation is required [30]. 
Epidemiological results indicate that the most common form of 
transmission is droplets expelled through face-to-face contact, 
coughing, or sneezing. Extended exposure to a person that has been 
infected (within at least 6-feet for 15 min) and short-term exposures 
to people that are symptomatic (e. g. coughing) are more likely to 
spread and are less likely to result in short exposures to 
asymptomatic contacts [31]. As smaller particles (aerosols) and 
large particles (droplets) are all clustered within a few meters, with 
physical distancing, and increased ventilation, the probability of 
transmission reduces. The respiratory-particle transmission (where 
an individual<2 m from an infected individual) spreads the bulk of 
SARS-CoV-2 infections over a small distance [32]. 
They invade the host cells via their viron spike protein and virus 
replication can also be closely linked to an angiotensin-converting 
enzyme 2 (ACE 2). The surface of pulmonary epithelial cells is 
heavily expressed by ACE2, which explains the recurrent lung 
involvement in SARS-CoV-2 [33-35].  
COVID-19 encompasses a full variety of signs ranging from elevated 
respiratory infections to dangerous pneumonia consistent with 
acute respiratory distress syndrome. Breathlessness, common cold, 
confusion, cough, diarrhea, fever, myalgia, runny nose, sneezing, 
vomiting, and wheezing are primary indicators of SARS-CoV-2 [34, 
36, 37]. Popular signs include in-hospital patients are breathlessness 
(53-80 percent), diarrhea (15-39 percent), dry cough (60-86 
percent), exhaustion (38 percent), fatigue (25 percent), fever (70-90 
percent), myalgias (15-44 percent), nausea or headache, or 
Husssain et al. 
Int J App Pharm, Vol 13, Issue 2, 2021, 48-58 
50 
rhinorrhea (7 percent). In approximately 3 percent of individuals 
with SARS-CoV-2, anosmia or ageusia can be the only symptom [38]. 
The fast development of respiratory collapse immediately after 
dyspnea and hypoxemia is a striking characteristic of SARS-CoV-2 
[39]. Fig. 2 represents the severity of COVID-19 symptoms according 
to a cohort study of>44,000 people. 
 
 
Fig. 2: A visual representation of a cohort of>44,000 patients in China and their varying illness severity [40] 
 
Treatment modalities 
Various Treatment options for Coronavirus disease (COVID-19) are 
being explored; apart from finding new treatment re-purposing or 
reprofiling of drugs, to treat COVID-19 is one of the centers of 
attention. Many drugs are under clinical trials, whereas Remdesivir 
has been approved by the United States (US) Food and drug 
administration and given emergency use authorization (EUA) on 
May 1 2020 to treat coronavirus disease [41]. Generally, treatment 
for COVID-19 focuses on relieving symptoms by use of supportive 
symptom care as well as general care [42]. Moieties attaching to the 
virus as well as the inhibiting molecules which can affect replication 
or transcription of the virus can be the prominent treatment options 
available. Several proteins of the virus can be targeted by molecules 
such as helicase as well as essential proteases [43]. Because of the 
whole genome sequenced and protein structure designing connected 
information, scientists have been able to fig. out possible drugs for 
the treatment of COVID-19 [44]. 
Anti-viral drugs 
What has been understood from previous virus outbreaks like SARS-
CoV-1 and middle east respiratory syndrome suggests the use of 
anti-virals like lopinavir-ritonavir and ribavirin and also other drugs 
like redeliver, arbidol, immunoglobulins, and interferons have been 
tried in the treatment of the coronavirus disease and found varying 
degrees of success [45]. Like antibiotics, the anti-viral agents do not 
directly target pathogens, rather they harm the growth and 
development of the viruses [46]. Through drug repurposing, various 
drugs have been suggested for COVID-19 potential treatment [47]. 
World Health Organization has begun the International Solidarity 
trial to assess the potential drugs for COVID-19 treatment which are 
already used for the anti-viral purpose [48].  
Remdesivir 
This drug was initially identified for Ebola and Marburg viral 
infections [49]. It works by the cessation of viral transcription by 
attacking the RNA-dependent RNA polymerase (RdRp) of viral origin 
and viral chain cessation [50]. This drug has an expansive spectrum 
of activity against other viruses like SARS-CoV and the Middle East 
respiratory syndrome [51,52]. This is the reason that it's used 
against these two above viruses that it has been tested for use in the 
case of COVID-19. Remdesivir has found to be effective in decreasing 
the viral lung load, checking the disease development as well as 
considerable bettering of the function of lungs in a mouse model 
used to inspect pathogenesis of SARS-CoV, prophylactic and post-
exposure administration of remdesivir [53]. Data from rhesus 
monkeys acknowledge that intravenous administration of 
remdesivir 10 mg/kg dose can bring about immense concentrations 
of active triphosphate form intracellularly for a 24-hour period, 
which encourages the possibility of the use of remdesivir in COVID-
19 treatment [49]. On a benevolent basis, 53 serious patients 
infected with SARS-CoV-2 infection, were administered with 
remdesivir and Grein et al. described 68% of patients exhibited a 
decrease in need of O2 requirement and thus shown substantial 
betterment and 57% of patients were no longer in need of ventilator 
support [54]. As per the Adaptive COVID-19 Treatment Trial in 
which 1063 participants (COVID-19 patients that were hospitalized) 
were administered with remdesivir and it was found that this drug 
reduced the recovery period for hospitalized patients suffering from 
pneumonia in COVID-19 [55]. In another trial analogous 
effectiveness was reported concerning remdesivir when it was given 
for 5 d in place of 10 d in serious COVID-19 patients with no need for 
ventilation regimen. Based on data from the Ebola outbreak and two 
trials, remdesivir received emergency use authorization by US-FDA 
[56]. As per another report with participants as patients having 
manifestations from ten days or less administered with remdesivir 
found better medical improvement than those receiving placebo but 
no analytically clinical advantage [57]. A case was recorded, which 
was found to have extreme betterment in the condition of the 
patient within one day after administering remdesivir [58].  
Lopinavir-ritonavir 
Lopinavir and ritonavir both are protease inhibitors utilized to 
reduce the infectivity of HIV-1 lopinavir are used in consolidation 
with ritonavir which leads to enhancement in the bioavailability 
because of protection from mitigation due to metabolic processes 
[59]. Apart from chloroquine and chlorpromazine, lopinavir has 
been shown to constrain duplication of MERS-CoV and SARS-CoV 
[60]. Acute respiratory distress syndrome was found to be reduced 
in subjects suffering from severe acute respiratory syndrome-
related to SARS-CoV, which were managed with the consolidation of 
lopinavir-ritonavir and ribavirin [61]. Because of the capability of 
lopinavir-ritonavir for use against SARS-CoV and MERS-CoV, these 
drugs have been proposed and tried for COVID-19. In China, 
lopinavir, ritonavir was endorsed for pneumonia treatment due to 
COVID-19 infection [62]. In another incidence, the subject was 
suffering from mild pneumonia due to COVID-19, which was 
administered with lopinavir-ritonavir and it was found that viral 
load was significantly reduced and viral titers were undiscoverable 
[63]. A clinical trial conducted in China where lopinavir-ritonavir 
was used showed no advantages in comparison to definitive classic 
care, and viral load was not declined in infected individuals with 
COVID-19 infection [64], but a decreased mortality was recorded in 
comparison to definitive classic care [53].  
Favipiravir 
This drug constrains the RdRp of viral RNA and has expansive anti-
viral actions for RNA viruses [65]. Favipiravir is authorized in japan 
for influenza treatment and it is opinionated to be a beneficial 
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treatment for COVID-19 Infection. In a limited sample size study of 
severe COVID-19 patients administered with combinations of 
favipiravir, heparins, and corticosteroid, it was found that favipiravir 
could somewhat restrain the mediators of inflammation but not 
completely. Findings report that favipiravir can have some 
advantage in COVID-19 infection treatment [66]. In another 
controlled open-label study, which in comparison to lopinavir-
ritonavir found that favipiravir had a swift clearance of viral load 
and a better pace of improving as found in the chest examination, in 
comparison to lopinavir-ritonavir it had enhanced effectiveness 
concerning the advancement of disease [67]. In a cohort study which 
was multicentered, of comparison of favipiravir and umifenovir, and 
it found that favipiravir had exceptional potency with recovery at 7th 
day and fever as well as cough extent was reduced [68].  
Ribavirin 
It also inhibits the Viral RdRp, because of its action against other 
novel coronaviruses, it is considered to be utilized in the 
management of SARS-CoV-2 infection [69]. Largely in the SARS 
epidemic, it was utilized but was bothered for, causing embryonic 
development disruptions in the fetus and hemolytic anemia [70]. In 
a phase II trial, consolidation of lopinavir-ritonavir, ribavirin, and 
interferon-β-1b lead to a contraction in the period of viral clearance 
[71]. The anti-viral actions in vitro of ribavirin were found at a 
concentration of 50 µg/ml, counteracting SARS-CoV infection [72].  
Umifenovir (Arbidol hydrochloride) 
It is a wider spectrum Anti-viral drug having effectiveness against 
influenza and parainfluenza etcetera [73]. A study including 111 
patients who were suffering from pneumonia-related to COVID-19 
was administered with an anti-viral regimen with including arbidol 
or not including arbidol, and it was reported that patients for those, 
arbidol was included along with anti-viral had a lower requirement 
of oxygen therapy and it was also noted that mildly symptomatic 
subjects were most helped with arbidol [74]. In another study 
including fifty patients’ effects of arbidol only and lopinavir-ritonavir 
treatment were observed and it was reported that patients only 
administered with arbidol, had untraceable viral load after a 
duration of two weeks of admitting them in contrast to 44% 
observed in patients who received lopinavir-ritonavir [75].  
Oseltamivir 
It is also used against influenza and it is potent neuraminidase 
inhibiting drug. In 1099 sufferers of COVID-19 of guan et al. showed 
the use of oseltamivir in 35.8 % of patients [76], and in 93% of 41 
sufferers of COVID-19 of Huang et al. were given oseltamivir [77] but 
no compelling findings were present to prove the efficacy of the drug 
oseltamivir. 
Nelfinavir  
This drug can be a potential drug for the treatment of SARS-CoV-2 
because it restricts the duplication, and also the cytopathogenic 
consequences of the COVID-19 causing virus in vitro. This drug acts 
by constraining the HIV protease [78, 79]. 
Hydroxychloroquine (HCQ) or chloroquine (CQ) 
For the past 70 y, HCQ and CQ are being utilized in malaria 
treatment and both these drugs have been found to have an action 
against the synthesis of protein of viruses as well as on access of the 
virus into and out of the host cell [80]. Various studies found that CQ 
decreases Angiotensin-converting enzyme-2 glycosylation and this 
way CQ inhibits attaching of SARS-CoV-2 to the host cell surface [81-
83]. In vitro CQ and HCQ were found to have restrictive actions for 
mRNA synthesis of novel Coronavirus 2019, whereas the HCQ is 
reported to have a better effect than CQ [84, 85]. As per a Chinese 
news broadcast of about 10 health care centers, for one hundred 
patients CQ strongly helped treat and decrease the advancement of 
COVID-19 [86]. In a study trial conducted on 36 subjects, 
Azithromycin and HCQ were given to patients either HCQ only or in 
a merger with azithromycin and it was found that all the subjects 
treated with the consolidation of azithromycin and HCQ had an 
untraceable load of SARS-CoV-2 and viral load was 57.1 % in those 
who were administered with HCQ alone [87]. As per a Chinese 
report, out of one hundred sufferers of COVID-19 those who were 
administered HCQ found to have better clinical results than the 
control subjects. HCQ is secure and competent for pneumonia 
associated with SARS-CoV-2 therapy as described by Gao et al. [86]. 
In a study, CQ was reported to decrease the viral concentration by 
the 6th day of treatment and lowered the need for oxygen as well as the 
requirement to shifted in ICU [88, 89]. In a Randomized trial of 491 
mild COVID-19 patients administered with HCQ and placebo, this 
study reported that there was not great differentiation between, 
alteration of the seriousness of patient condition by 14 d between 
placebo and HCQ group and it was reported that HCQ does not 
alleviate symptom seriousness in non-hospitalized less severe COVID-
19 patients [90]. World health organization terminated trials being 
conducted for determining the effectiveness of HCQ because of no 
reduction in death rate by the drug in the sufferers of COVID-19 [91].  
Antibiotics and antiparasitics 
Carrimycin 
National Medical Products Administration, china authorized 
carrimycin for use in the treatment of upper respiratory tract 
infections this drug was formed for this purpose [92]. On 520 
COVID-19 sufferers in Beijing youan health care center, randomized 
open-labeled multiple center trial is being conducted to assess 
clinical effectiveness and safety [93].  
Azithromycin  
It is an Antibiotic belonging to the Macrolides category, it works by 
preventing the growth of bacteria, apart from antibacterial actions it 
has antiviral actions as well. It has been utilized in the treatment of 
infections related to viruses in the upper respiratory tract [94]. 
Moreover, azithromycin has been thought to be preventive against 
serious respiratory infection, in nursey children when given it is 
given to sufferers of virus-related infections [95]. The latest study 
revealed that for treating 20 serious SARS-CoV-2 infections 
sufferer’s azithromycin considerably strengthened the effectiveness 
of HCQ, there was increased virus clearing efficiency after giving 
these two drugs [96]. As per Masahi et al. macrolides only or when 
given together with HCQ are efficacious to treat COVID-19 [97].  
Ivermectin 
In 1975 this drug was unearthed and its utilization was started in 
1981 [98, 99]. This is a US-FDA authorized drug and utilized in the 
treatment of various diseases like scabies, malaria, enterobiasis, etc. 
This drug is also acknowledged to have anti-viral actions against 
some viruses in vitro [100-103]. As per a study, conducted it was 
found that ivermectin constrains the duplication of SARS-CoV-2 
virus in the in vitro conditions [104]. In a study on 100 COVID-19 
patients treated by administering ivermectin and doxycycline 
together, and this was reported that when these two drugs given 
together were very competent in eliminating viral load in less severe 
as well as moderately affected COVID-19 sufferers [105]. In a pilot 
trial conducted to assess the efficacy of ivermectin as an additional 
treatment with HCQ and azithromycin on 87 COVID-19 sufferers, it 
was reported that administration of additional ivermectin therapy to 
HCQ and azithromycin regimen leads to a lesser hospital stay, 
greater efficacy, and better safety in comparison to control group 
[106]. As per a randomized controlled trial conducted in Baghdad, 
Iraq on 70 COVID sufferers administered with ivermectin and 
doxycycline and other 70 COVID sufferers, treated with standard 
therapy and it was reported that ivermectin along with doxycycline 
decreased time to recover and also death rate was declined in the 
serious patients [107]. 
Interferons 
Interferons are existing by nature proteins, which are formed by 
immune cells of the body. Interferons can be of alpha, beta, and 
gamma types, immune responses are furthered opposing attacking 
antigens [108]. Because of distinct cell surface molecules, toll-like 
receptors get stimuli and thus a-helical cytokines are secreted called 
interferons. For hepatitis, interferon-alpha (IFN-α) is extensively 
utilized, it's a wide scope anti-viral drug. IFN-α is reported to 
decrease the replication of SARS-CoV-2 in the in vitro conditions 
[109]. Interferon-beta (IFN-β) is a naturally existing protein 
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molecule that puts together the anti-viral bodily responses [70]. IFN-
α and IFN-β two together have adverse effects on severe acute 
respiratory syndrome coronavirus 2 in the in vitro conditions [110, 
111]. Interferon-beta showed compelling activity versus the MERS-
CoV in vitro [112]. IFN-α and IFN-β showed synergism with ribavirin 
against SARS-CoV as well as both alpha and beta interferons shows 
synergistic effects against SARS-CoV [113-116]. Using Recombinant 
Type-I IFN-α in an in vitro condition study, it was found that there 
was a considerable reduction in the reproduction of the SARS-CoV-2 
[117]. The guidelines given by the National health commission and 
state administration of Traditional Chinese medicine suggested 
various drugs for SARS-CoV-2 treatment, along with other drugs 
IFN-α is also suggested [118].  
Monoclonal antibodies 
Monoclonal antibodies made synthetically at laboratory scale mimes 
the antibodies existing in nature. As per studies conducted on SARS-
CoV and MERS pathogenesis, and it was advised that during a severe 
illness, interleukin-6 (IL-6) and other pro-inflammatory cytokines 
are released [119]. In COVID sufferers’ antibodies can bring about 
the rapid effect. 
Tocilizumab 
It is a monoclonal antibody that acts in opposition to IL-6, utilized as 
an agent that suppresses immunity. Considerable harm to the lungs 
is brought about by the activation of the immune response as well as 
the release of cytokines, and in the cytokine storm, IL-6 seems to 
have a leading role as found in a Chinese case series [120]. Because 
tocilizumab can bar the release of IL-6 it can be protective for 
COVID-19 sufferers [121]. In a small sample-sized trial conducted in 
china on 21 serious COVID-19 sufferers, and they were administered 
with tocilizumab, and it was reported that fever was controlled in 
every patient, whereas for 75% of patient’s oxygen requirement was 
decreased, and in 90.5% of patient’s lung lesions were resolved, C-
reactive proteins were lowered and came to regular levels in 84.2 % 
of the COVID-19 patients [122]. In a reflective study, it was reported 
that C-reactive protein was considerably lowered after giving 
tocilizumab to fifteen COVID-19 patients [123]. In Civic health care 
centers, Mumbai tocilizumab was used to treat patients and it was 
found to be quite efficacious [121].  
Sarilumab 
It is also an IL-6 receptor inhibitor utilized for rheumatoid arthritis. 
As per a phase II trial, for whom result data is given in a press 
release, and it was disclosed that in comparison to the placebo, 
sarilumab was related to the lesser death rate, increased hospital 
discharges, and better clinical improvement [124].  
Corticosteroids 
Corticosteroids belong to the category of steroidal hormones, and 
they act as key aspects related to inflammation and immune 
responses. Because of the effectiveness of the corticosteroids on 
various interleukins like IL-6, interleukin 1(IL-1), etc. these have 
been extensively utilized in the SARS-CoV epidemics [125, 126], But 
the researches involving corticosteroids in the treatment of MERS 
and SARS reported no considerable effect on death rate and 
infection clearance was also found to be disrupted [127]. RECOVERY 
(Randomized Evaluation of COVid-19 therapy) trial regarding 
dexamethasone, its primary results have shown that dexamethasone 
decreased the death rate in patients who were on mechanical 
respiratory support [128, 129]. Recovery trial data about 
dexamethasone shows strong proof that the drug can be utilized in 
those sufferers who are at mechanical respiratory support; also this 
trial gives firm proof about the use of glucocorticoids which also lead 
to approval of dexamethasone by the National Health Service, 
England [130]. Dexamethasone also received authorization from the 
world health organization for very serious patients [131].  
Angiotensin receptor blockers 
For novel coronavirus 2019 Angiotensin-Converting Enzyme-2 
(ACE2) is a site of binding, and the attachment with ACE2 lead to a 
reduction of ACE2, which in turn leads to increased production of 
angiotensin by angiotensin-converting enzyme, and elevated 
angiotensin leads to elevated excitation of angiotensin receptor 1, as 
a consequence of that there can be lung damage, and speculation is 
that angiotensin receptor 1 blocker such as losartan can be a 
potential treatment for Lung damage in COVID-19 infection [132].  
Convalescent plasma 
In various disease conditions like influenza as well as SARS and 
serious ebolavirus infection, convalescent plasma has been utilized 
as a concluding alternative to cause betterment in the condition of 
severe sufferers [133, 134]. The proposed reasoning for the 
effectiveness of the plasma is because of the presence of 
immunoglobulin antibodies in the blood of patients successfully 
treated and recovered from COVID-19, which can lead to the 
elimination of viral presence in the bloodstream [53]. As per the case 
series by Shen et al., Convalescent plasma therapy, when given to 
five severe SARS-CoV-2 patients, resulted in the betterment of 
clinical outcomes [134]. In other proven treatments, convalescent 
plasma has previously been used, but it has been tried and found to 
be effective in this case, and the procedures at different facilities 
have shown that it demonstrates the same high degree of 
effectiveness and protection [135]. Further clinical trials and studies 
are needed to evaluate the usage of convalescent plasma in COVID-
19 treatment. 
Herbal therapy  
Because of the previous usage in SARS and swine flu, traditional Chinese 
herbal medicine was also considered as a therapy for the management of 
COVID-19, whereas strong proof that justifies the effectiveness of these 
drugs in the current pandemic is still not available. Traditional Chinese 
medicines like Huangqi, Gancao, and fangfeng, etc. were utilized in china 
in the SARS-CoV-2 pandemic [136, 137]. A chemical constituent obtained 
from roots of licorice called Glycyrrhizin is reported to restrict 
duplication of SARS-CoV in vitro [138]. Another flavonoid, Baicalin also 
found to have activity against SARS-CoV in vitro [139]. In India 
Ayurvedic experts via the government of India, gave precautionary 
measures to build immunity against COVID-19 such as taking lukewarm 
water, rinsing the mouth with oil, use of ghee in the nose, etc. [140]. 
Arsenic album, which is a homeopathic medicine, has been suggested in 
managing the COVID-19 [141]. 
Miscellaneous agents 
Because of the pulmonary microthrombi in severely sick SARS-CoV-
2 sufferers, thus anti-coagulation agents expected to be used in the 
treatment of the disease, COVID-19 is related to excessive abnormal 
blood clot formation, which in turns is the reason for the greater 
death rate. Heparin has been found to decrease the death rate in 
serious COVID-19 sufferers [142]. Low molecular weight heparins 
have been endorsed in the prevention of development of thrombosis 
and as a prophylactic treatment for COVID-19 patients [143, 144].  
Nitazoxanide has a potent wide spectrum, anti-viral actions as it has 
anti-viral actions against various kinds of viruses like coronaviruses, 
hepatitis c, and b as well as influenza viruses. In the in vitro 
conditions, this drug has been found to constrain the novel 
coronavirus 2019 at low concentrations [99]. Apart from having 
anti-viral activities, nitazoxanide inhibits inflammatory cytokines 
like IL-6 and IL-1, etc. In a study on mice, it was reported that 
nitazoxanide reduced plasma concentrations of IL-6 after 
administration of nitazoxanide in comparison to the vehicle [145]. 
Nitazoxanide is proposed to do the betterment in the cytokine 
storm, which is faced by serious COVID-19 sufferers [146].  
Camostat mesylate restricts the protease serine 2 of the host, thus 
averts the access of the novel coronavirus 2019 to the cell of the host 
in vitro [147]. But more studies are required to show anti-viral 
actions against novel coronavirus 2019.  
A cough suppressing agent, Bromhexine hydrochloride, which is a 
mucus clearing agent from upper respiratory airways, it is accepted 
that bromhexine inhibits firmly the protease serine 2, which has an 
important part in the entry of novel coronavirus 2019, so clinical 
studies and trials are required to assess its efficiency [148]. 
Janus kinase inhibitor Baricitinib is authorized for utilization in 
rheumatoid arthritis; this drug can be efficacious in treating the 
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COVID-19 to constrain the inflammatory activity as well as access of 
virus to host cell [149,150]. Baricitinib has a strong inclination 
towards AP2-associated protein kinase 1 (AAK1), which governs the 
endocytosis [151]. Interruption of endocytosis can lead to the 
prohibition of access of virus into the host cell [152]. Janus kinase 
inhibitors are found to be efficacious opposite the effects of cytokine 
levels as found in SARS-CoV-2 sufferers [77]. 
Valproate has anti-viral and anti-inflammatory abilities; because of that, 
this drug may avert lung damage due to the effects of COVID-19 [153].  
Intravenous gamma globulins (IVIGs) were utilized broadly in the 
SARS outbreak in Singapore by Thomas et al. [154]. Few case series 
reported that a greater dose of IVIG can alleviate the further advance 
of the disease and make the clinical outcomes better [155]. In critical 
SARS-CoV patients, IVIG as an adjuvant therapy can decrease the 
requirement of respiratory support, decrease the death rate, and 
also decrease the time spent at the hospital [156]. Bacillus Calmette–
Guérin (BCG) vaccine can persuade metabolic and epigenetic 
alterations to cause innate immunity its efficacious act in case of 
SARS, for COVID-19 this vaccine has been suggested [157]. 
Vitamins and supplements: Because of the immunomodulation 
properties of Vitamin D, versus the COVID-19 as reported in few 
clinical trials, it was able to avert the infection in the beginning 
stages, as well as in more inflammatory levels during COVID-19 
infection [158].  
Vitamin C also has immunity modulating, anti-oxidant as well as 
anti-viral actions; this supplement has various mechanisms related 
to immune responses and has direct activities against viruses. 
Vitamin C drastically decreases the pro-inflammatory cytokines, 
which are related to crucial COVID-19 condition [159].  
Also, supplements like iron, selenium, zinc, and other trace elements 
are suggested for use in the treatment of COVID-19 disease [73].  
Vaccines 
Vaccines are amongst the most economic and therefore important 
public health initiatives. Vaccines are indeed very unique because 
they improve health, defend people, families, and whole societies, 
and speedily help to save lives [160]. Vaccines are now important in 
preventing the spread of disease and prevention of SARS-COV-2 
contamination. In its development phase, nearly 100 vaccines have 
been developed and 10 are being clinically assessed according to the 
recent update from the WHO [161]. Table 3 shows the lists of 
advanced vaccines and their information. 
 
Table 3: List of advanced COVID-19 vaccines that are in Phase 3 and approved by some countries 
Manufacturer Vaccine name Type Efficacy Clinical phase 
Pfizer-BioNTech BNT162b2 mRNA 95% Phase 3 
University of Oxford-AstraZeneca ChAdOx1 nCoV-19 Adenovirus 90% Phase 3 
Moderna-US National Institutes of Health mRNA-1273 mRNA 94.5% Phase 3 
CanSino Biologics-Academy of Military 
Medical Sciences 
Ad5-nCoV Adenovirus Unknown Phase 3 
Gamaleya Research Institute Sputnik V Adenovirus Unknown Phase 3 
Sinopharm BBIBP-CorV Inactivated 86% Phase 3 
Zydus ZyCov-D DNA Unknown Phase 3 
CureVac CVnCoV mRNA Unknown Phase 3 
Sinovac CoronaVac Inactivated Unknown Phase 3 
Bharat Biotech, Indian Council of Medical 
Research, and National Institute of 
Virology 
Covaxin Inactivated Unknown Phase 3 
 
Pfizer-BioNTech vaccine 
This vaccine is also named BNT162b2, is the earliest vaccine to be 
referred to US-FDA for emergency use authorization. On November 
20, it was submitted to US-FDA after completion of the phase-3 trial 
[162]. The Pfizer-BioNTech vaccine is not given approval by US-FDA 
but Emergency use authorization has been granted [163]. As per 
conclusions given in the press-release, this vaccine was found to be 
95% efficacious after administering the first dose after 28 d in 170 
COVID-19 sufferers. The vaccine is expected to be priced at £15 for 
each dose. Pfizer has stated that this vaccine can be made accessible 
to increased risk populations in the US [164]. 
University of oxford-astra zeneca vaccine 
ChAdOx1 nCoV-19 vaccine has various trials in different countries of 
the world, whereas trials were initiated in the United Kingdom, and 
in Brazil, US, and South Africa trials have branched out. Provisional 
results of the phase 3 trial on 131 patients advised 90 % 
effectiveness of the vaccine [165]. The company intends to make the 
vaccine available in the whole world and not just in the developed 
countries and is estimated to be priced at £3 for each dose, it can be 
stored at a temperature range of 2-8 degrees Celsius [164].  
Moderna-US national institutes of health vaccine 
US biotechnology company Moderna, in association with the US 
National Institute of health, prepared mRNA-1273 vaccine, which is 
found to be 94.5% efficacious as per provisional results from phase 
3 trial in the US [166]. Soon, Moderna aims to receive emergency use 
authorization from US-FDA and apply for the same in the near 
future. The per-dose price is quite high than the other two late phase 
vaccine candidates, it is expected to be £25 for each dose [164]. 
CanSino biologics-academy of military medical sciences vaccine 
CanSino Biologics in partnership with an academy of military 
medical sciences, institute of biology, made a vaccine named Ad5-
nCoV, this vaccine candidate asserts whole length spike, a 
glycoprotein from viral strain Wuhan-Hu-1. Phase 1 trial on 108 
patients gave promising results. Neutralising antibodies were 
elevated at day 14 considerably, and antibodies were highest at day 
28 after vaccination [167]. In the phase 2 trial, it was showed that 
the vaccine persuades the immune response in most of the patients 
[168]. In June 2020, before the commencement of the phase 3 trial, 
this vaccine became approved and it was declared as approved by 
CanSino Biologics and institute of biology, academy of military 
medical sciences, china [169]. From August, the phase 3 trial was 
initiated in countries like Pakistan, China, and Saudi Arabia.  
Gamaleya research institute vaccine 
A unit of the Russian Health Ministry, Gamaleya Research Institute, 
developed a vaccine, sputnik V with an effectiveness of 91.4 percent 
as per announcement in a press release [170]. In the randomized 
phase 1/2 trial two studies, including 76 patients, 38 in each found 
that vaccine has effectiveness in generating immune responses in 
patients [171]. Initial data from the phase 3 trial was provided and it 
was announced that the vaccine is efficacious. Phase 3 trial results 
are under review by a few countries, including India [172]. 
Sinopharm 
Presently, Sinopharm working on two vaccine candidates, which are 
attenuated virus, out of the two one was developed by the Beijing 
Institute of Biological Products. As per the phase 1/2 trial, the 
BBIBP-CorV vaccine is secure at all dosages tested. On day 42, 
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immune responses were persuaded in all patients who received 
vaccine dose [173]. The United Arab Emirates gave emergency 
approval to the vaccine to be administered to health care people 
[174]. On December 9 Beijing institute vaccine candidate received 
full authorization to be used in the United Arab Emirates, the vaccine 
being at efficacy 86% [175]. Bahrain also approved the vaccine on 
basis of data, it also participated in phase 3 trials [176]. Another 
vaccine by Sinopharm was made by the Wuhan Institute of 
Biological Products. The phase 1/2 trial reported that the vaccine 
was able to induce antibodies in patients. In various countries, the 
vaccine is under phase 3 trials [177].  
CONCLUSION 
With COVID-19 appearing to spread, more infections are likely to occur 
in various regions, parts of the globe within the general public. The 
society and their family members, as well as the general public and 
health service providers, therefore need to be informed as accurately as 
possible. Since we still have the COVID-19 epidemic worldwide, we need 
to efficiently and effectively make preparations ourselves. Our objective 
should be to provide adequate clinical care and patient support whilst 
adequately protecting healthcare professionals. 
In the last two decades, we have been alerted thrice. First, in 2002, 
the SARS-CoV spread rapidly to 32 nations around the globe then in 
2012 a MERS-CoV outbreak was later experienced worldwide. The 
newly developed SARSCoV-2 is certainly a warning in recent times. 
SARS-CoV-2 is confirmed by its binding with ACE2 in the lung. ACE2 
is highly expressed in other tissues, such as the bile duct, esophagus, 
gastrointestinal organ, liver, kidneys, and testis as well as in 
pulmonary tissue.  
In addition to new medicines and old drug clinical testing, SARS-
CoV-2 vaccines must also be designed and developed. SARS-CoV and 
MERS-CoV lessons indicate that SARS-CoV-2 research should focus 
on the creation of animal models to summarize the different aspects 
of human disease and the vaccine safety and effectiveness 
determinants. Moreover, positive news in the development of 
vaccines suggests that new vaccines will be available on the market 
soon and a bowl of immunity against this virus can be established, 
thus limiting the spread and eradication of this deadly virus from the 
surface of the world as with so many viruses. 
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